Controlled Drugs and Substances Act

Her Majesty, by and with the advice and consent of the Senate and House of Commons of Canada, enacts as follows:

Short Title

Interpretation

Part I · Offences and Punishment

Part I.1 · Evidence-based Diversion Measures

Part II · Enforcement

Part III · Disposition

Part IV · Administration and Compliance

Part V · Administrative Orders for Contraventions of Designated Regulations

Part VI · General

Part VII · Transitional Provisions, Consequential and Conditional Amendments, Repeal and Coming into Force

Schedule I · (Sections 2, 4 to 7.1, 10, 29, 55 and 60)

1 Opium Poppy (Papaver somniferum), its preparations, derivatives, alkaloids and salts, including:(1) Opium(2) Codeine (methylmorphine)(3) Morphine (7,8–didehydro–4,5–epoxy–17–methylmorphinan–3,6–diol)(4) Thebaine (paramorphine)and the salts, derivatives and salts of derivatives of the substances set out in subitems (1) to (4), including:(5) Acetorphine (acetyletorphine)(6) Acetyldihydrocodeine (4,5–epoxy–3–methoxy–17–methylmorphinan–6–ol acetate)(7) Benzylmorphine (7,8–didehydro–4,5–epoxy–17–methyl–3–(phenylmethoxy) morphinan–6–ol)(8) Codoxime (dihydrocodeinone O–(carboxymethyl) oxime)(9) Desomorphine (dihydrodeoxymorphine)(10) Diacetylmorphine (heroin)(11) Dihydrocodeine (4,5–epoxy–3–methoxy–17–methylmorphinan–6–ol)(12) Dihydromorphine (4,5–epoxy–17–methylmorphinan–3,6–diol)(13) Ethylmorphine (7,8–didehydro–4,5–epoxy–3–ethoxy–17–methylmorphinan–6–ol)(14) Etorphine (tetrahydro–7alpha–(1–hydroxy–1–methyl-butyl)–6,14–endo–ethenooripavine)(15) Hydrocodone (dihydrocodeinone)(16) Hydromorphinol (dihydro–14–hydroxymorphine)(17) Hydromorphone (dihydromorphinone)(18) Methyldesorphine (delta-6-deoxy-6-methylmorphine)(19) Methyldihydromorphine (dihydro–6–methylmorphine)(20) Metopon (dihydromethylmorphinone)(21) Morphine–N–oxide (morphine oxide)(22) Myrophine (benzylmorphine myristate)(23) Nalorphine (N–allylnormorphine)(24) Nicocodine (6–nicotinylcodeine)(25) Nicomorphine (dinicotinylmorphine)(26) Norcodeine (N–desmethylcodeine)(27) Normorphine (N–desmethylmorphine)(28) Oxycodone (dihydrohydroxycodeinone)(29) Oxymorphone (dihydrohydroxymorphinone)(30) Pholcodine (3–[2–(4–morpholinyl)ethyl]morphine)(31) Thebacon (acetyldihydrocodeinone)but not including(32) Apomorphine (5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol) and its salts(33) Cyprenorphine (N-(cyclopropylmethyl)-6,7,8,14-tetrahydro-7alpha-(1-hydroxy-1-methylethyl)-6,14-endo-ethenonororipavine) and its salts(34) Nalmefene (17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol) and its salts(34.1) Naloxone (4,5alpha-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one) and its salts(34.2) Naltrexone (17-(cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one) and its salts(34.3) Methylnaltrexone (17-(cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium) and its salts(34.4) Naloxegol (4,5alpha-epoxy-6alpha-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propenyl)morphinan-3,14-diol) and its salts(35) Narcotine (6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo [4,5-g]isoquinolin-5-yl)-1(3H)-isobenzofuranone) and its salts(36) Papaverine (1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline) and its salts(37) Poppy seed2 Coca (Erythroxylum), its preparations, derivatives, alkaloids and salts, including:(1) Coca leaves(2) Cocaine (benzoylmethylecgonine)(3) Ecgonine (3–hydroxy–2–tropane carboxylic acid)but not including(4) ¹²³l-ioflupane3 Phenylpiperidines, their intermediates, salts, derivatives and analogues and salts of intermediates, derivatives and analogues, including:(1) Allylprodine (3–allyl–1–methyl–4–phenyl–4–piperidinol propionate)(2) Alphameprodine (alpha–3–ethyl–1–methyl–4–phenyl–4–piperidinol propionate)(3) Alphaprodine (alpha–1,3–dimethyl–4–phenyl–4–piperidinol propionate)(4) Anileridine (ethyl 1–[2–(p–aminophenyl)ethyl]–4–phenylpiperidine–4–carboxylate)(5) Betameprodine (beta–3–ethyl–1–methyl–4–phenyl–4–piperidinol propionate)(6) Betaprodine (beta–1,3–dimethyl–4–phenyl–4–piperidinol propionate)(7) Benzethidine (ethyl 1–(2–benzyloxyethyl)–4–phenylpiperidine–4–carboxylate)(8) Diphenoxylate (ethyl 1–(3–cyano–3,3–diphenylpropyl)–4–phenylpiperidine–4–carboxylate)(9) Difenoxin (1–(3–cyano–3,3–diphenylpropyl)–4–phenylpiperidine–4–carboxylate)(10) Etoxeridine (ethyl 1–[2–(2–hydroxyethoxy) ethyl]–4–phenylpiperidine–4–carboxylate)(11) Furethidine (ethyl 1–(2–tetrahydrofurfury loxyethyl)–4–phenylpiperidine–4–carboxylate)(12) Hydroxypethidine (ethyl 4–(m–hydroxyphenyl)–1–methylpiperidine–4–carboxylate)(13) Ketobemidone (1–[4–(m–hydroxyphenyl)–1–methyl–4–piperidyl]–1–propanone)(14) Methylphenylisonipecotonitrile (4–cyano–1–methyl–4–phenylpiperidine)(15) Morpheridine (ethyl 1–(2–morpholinoethyl)–4–phenylpiperidine–4–carboxylate)(16) Norpethidine (ethyl 4–phenylpiperidine–4–carboxylate)(17) Pethidine (ethyl 1–methyl–4–phenylpiperidine–4–carboxylate)(18) Phenoperidine (ethyl 1–(3–hydroxy–3–phenylpropyl)–4–phenylpiperidine–4–carboxylate)(19) Piminodine (ethyl 1–[3–(phenylamino)propyl]–4–phenylpiperidine–4–carboxylate)(20) Properidine (isopropyl 1–methyl–4–phenylpiperidine–4–carboxylate)(21) Trimeperidine (1,2,5–trimethyl–4–phenyl–4–piperidinol propionate)(22) Pethidine Intermediate C (1–methyl–4–phenylpiperidine–4–carboxylate)but not including(23) Carperidine (ethyl 1-(2-carbamylethyl)-4-phenylpiperidine-4-carboxylate) and its salts(24) Oxpheneridine (ethyl 1-(2-hydroxy-2-phenylethyl)-4-phenylpiperidine-4-carboxylate) and its salts4 Phenazepines, their salts, derivatives and salts of derivatives including:(1) Proheptazine (hexahydro–1,3–dimethyl–4–phenyl–1H–azepin–4–ol propionate)but not including(2) Ethoheptazine (ethyl hexahydro-1-methyl-4-phenylazepine-4-carboxylate) and its salts(3) Metethoheptazine (ethyl hexahydro-1,3-dimethyl-4-phenylazepine-4-carboxylate) and its salts(4) Metheptazine (methylhexahydro-1,2-dimethyl-4-phenylazepine-4-carboxylate) and its salts5 Amidones, their intermediates, salts, derivatives and salts of intermediates and derivatives including:(1) Dimethylaminodiphenylbutanonitrile (4–cyano–2–dimethylamino–4,4–diphenylbutane)(2) Dipipanone (4,4–diphenyl–6–piperidino–3–heptanone)(3) Isomethadone (6–dimethylamino–5–methyl–4,4–diphenyl–3–hexanone)(4) Methadone (6–dimethylamino–4,4–diphenyl–3–heptanone)(5) Normethadone (6–dimethylamino–4,4–diphenyl–3–hexanone)(6) Norpipanone (4,4–diphenyl–6–piperidino–3–hexanone)(7) Phenadoxone (6–morpholino–4,4–diphenyl–3–heptanone)6 Methadols, their salts, derivatives and salts of derivatives including:(1) Acetylmethadol (6–dimethylamino–4,4–diphenyl–3–heptanol acetate)(2) Alphacetylmethadol (alpha–6–dimethylamino–4,4–diphenyl–3–heptanol acetate)(3) Alphamethadol (alpha–6–dimethylamino–4,4–diphenyl–3–heptanol)(4) Betacetylmethadol (beta–6–dimethylamino–4,4–diphenyl–3–heptanol acetate)(5) Betamethadol (beta–6–dimethylamino–4,4–diphenyl–3–heptanol)(6) Dimepheptanol (6–dimethylamino–4,4–diphenyl–3–heptanol)(7) Noracymethadol (alpha–6–methylamino–4,4–diphenyl–3–heptanol acetate)7 Phenalkoxams, their salts, derivatives and salts of derivatives including:(1) Dimenoxadol (dimethylaminoethyl 1–ethoxy–1,1–diphenylacetate)(2) Dioxaphetyl butyrate (ethyl 2,2–diphenyl–4–morpholinobutyrate)(3) Dextropropoxyphene ([S-(R*,S*)]-alpha-[2-(dimethylamino)-1-methylethyl]-alpha-phenylbenzeneethanol, propanoate ester)8 Thiambutenes, their salts, derivatives and salts of derivatives including:(1) Diethylthiambutene (N,N–diethyl–1–methyl–3,3–di–2–thienylallylamine)(2) Dimethylthiambutene (N,N,1–trimethyl–3,3–di–2–thienylallylamine)(3) Ethylmethylthiambutene (N–ethyl–N,1–dimethyl–3,3–di–2–thienylallylamine)9 Moramides, their intermediates, salts, derivatives and salts of intermediates and derivatives including:(1) Dextromoramide (d–1–(3–methyl–4–morpholino–2,2–diphenylbutyryl)pyrrolidine)(2) Diphenylmorpholinoisovaleric acid (2–methyl–3–morpholino–1,1–diphenylpropionic acid)(3) Levomoramide (l–1–(3–methyl–4–morpholino–2,2–diphenylbutyryl)pyrrolidine)(4) Racemoramide (d,l–1–(3–methyl–4–morpholino–2,2–diphenylbutyryl) pyrrolidine)10 Morphinans, their salts, derivatives and salts of derivatives including:(1) Buprenorphine (17–(cyclopropylmethyl)–alpha–(1,1–dimethylethyl)–4,5–epoxy–18,19–dihydro–3–hydroxy–6–methoxy–alpha–methyl–6,14–ethenomorphinan–7–methanol)(2) Drotebanol (6beta,14–dihydroxy–3,4–dimethoxy–17–methylmorphinan)(3) Levomethorphan (l–3–methoxy–17–methylmorphinan)(4) Levorphanol (l–3–hydroxy–17–methylmorphinan)(5) Levophenacylmorphan (l–3–hydroxy–17–phenacylmorphinan)(6) Norlevorphanol (l–3–hydroxymorphinan)(7) Phenomorphan (3–hydroxy–17–(2–phenylethyl)morphinan)(8) Racemethorphan (d,l-3-methoxy-17-methylmorphinan)(9) Racemorphan (d,l–3–hydroxy–N–methylmorphinan)but not including(10) Dextromethorphan (d-1,2,3,9,10, 10a-hexahydro-6-methoxy-11-methyl-4H-10,4a-iminoethanophenanthren) and its salts(11) Dextrorphan (d-1,2,3,9,10,10a-hexahydro-11-methyl-4H-10,4a-iminoethanophenanthren-6-ol) and its salts(12) Levallorphan (l-11-allyl-1,2,3,9,10,10a-hexahydro-4H-10,4a-iminoethanophenanthren-6-ol) and its salts(13) Levargorphan (l-11-propargyl-1,2,3,9,10,10a-hexahydro-4H-10,4a-iminoethanophenanthren-6-ol) and its salts(14) Butorphanol (l-N-cyclobutylmethyl-3,14-dihydroxymorphinan) and its salts(15) Nalbuphine (N-cyclobutylmethyl-4,5-epoxy-morphinan-3,6,14-triol) and its salts11 Benzazocines, their salts, derivatives and salts of derivatives including:(1) Phenazocine (1,2,3,4,5,6–hexahydro–6,11–dimethyl–3–phenethyl–2,6–methano–3–benzazocin–8–ol)(2) Metazocine (1,2,3,4,5,6–hexahydro–3,6,11–trimethyl–2,6–methano–3–benzazocin–8–ol)(3) Pentazocine (1,2,3,4,5,6–hexahydro–6,11–dimethyl–3–(3–methyl–2–butenyl)–2,6–methano–3–benzazocin–8–ol)but not including(4) Cyclazocine (1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(cyclopropylmethyl)-2,6-methano-3-benzazocin-8-ol) and its salts12 Ampromides, their salts, derivatives and salts of derivatives including:(1) Diampromide (N–[2–(methylphenethylamino)propyl] propionanilide)(2) Phenampromide (N-((1-methyl-2-piperidino) ethyl) propionanilide)(3) Propiram (N–(1–methyl–2–piperidinoethyl)–N–2–pyridylpropionamide)13 Benzimidazoles, their salts, derivatives and salts of derivatives including:(1) Clonitazene (2–(p–chlorobenzyl)–1–diethylaminoethyl–5–nitrobenzimidazole)(2) Etonitazene (2–(p–ethoxybenzyl)–1–diethylaminoethyl–5–nitrobenzimidazole)(3) Bezitramide (1–(3–cyano–3,3–diphenylpropyl)–4–(2–oxo–3–propionyl–1–benzimidazolinyl)–piperidine)14 Phencyclidine (1-(1-phenylcyclohexyl)piperidine), its salts, derivatives and analogues and salts of derivatives and analogues, including:(1) Ketamine (2-(2-chlorophenyl)-2-(methylamino)cyclohexanone)15 Piritramide (1–(3–cyano–3,3–diphenylpropyl)–4–(1–piperidino)piperidine–4–carboxylic acid amide), its salts, derivatives and salts of derivatives16 Fentanyls, their salts, derivatives, and analogues and salts of derivatives and analogues, including:(1) Acetyl–alpha–methylfentanyl (N–[1–(alpha–methylphenethyl)–4–piperidyl] acetanilide)(2) Alfentanil (N–[1–[2–(4–ethyl–4,5–dihydro–5–oxo–1H–tetrazol–1–yl)ethyl]–4–(methoxymethyl)–4–piperidyl]propionanilide)(3) Carfentanil (methyl 4–[(1–oxopropyl)phenylamino]–1–(2–phenethyl)–4–piperidinecarboxylate)(4) p-Fluorofentanyl (4′-fluoro-N-(1-phenethyl-4-piperidyl) propionanilide)(5) Fentanyl (N–(1–phenethyl–4–piperidyl) propionanilide)(6) Beta–Hydroxyfentanyl (N–[1–(beta–hydroxyphenethyl)–4–piperidyl] propionanilide)(7) Beta–Hydroxy–3–methylfentanyl (N–[1–(beta–hydroxyphenethyl)–3–methyl–4–piperidyl] propionanilide)(8) Alpha–Methylfentanyl (N–[1–(alpha–methylphenethyl)–4–piperidyl] propionanilide)(9) Alpha–Methylthiofentanyl (N–[1–[1–methyl–2–(2–thienyl) ethyl]–4–piperidyl] propionanilide)(10) 3–Methylfentanyl (N–(3–methyl–1–phenethyl–4–piperidyl) propionanilide)(11) 3–Methylthiofentanyl (N–[3–methyl–1–[2–(2–thienyl) ethyl]–4–piperidyl] propionanilide)(11.1) Remifentanil (dimethyl 4-carboxy-4-(N-phenylpropionamido)-1-piperidinepropionate)(12) Sufentanil (N–[4–(methoxymethyl)–1–[2–(2–thienyl)ethyl]–4–piperidyl] propionanilide)(13) Thiofentanyl (N–[1–[2–(2–thienyl)ethyl]–4–piperidyl] propionanilide)(14) 4-Anilino-N-phenethylpiperidine (ANPP) (N-phenyl-1-(2-phenylethyl)piperidine-4-amine), its derivatives and analogues and salts of derivatives and analogues17 Tilidine (ethyl-2-(dimethylamino)-1-phenyl-3-cyclohexene-1-carboxylate), its salts, derivatives and salts of derivatives17.1 Methylenedioxypyrovalerone (MDPV), its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues18 Methamphetamine (N,alpha-dimethylbenzeneethanamine), its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues19 Amphetamines, their salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues including:(1) amphetamine (alpha-methylbenzene-ethanamine)(2) N-ethylamphetamine (N-ethyl-alpha-methylbenzeneethanamine)(3) 4-methyl-2,5-dimethoxyamphetamine (STP) (2,5-dimethoxy-4,alpha-dimethylbenzeneethanamine)(4) 3,4-methylenedioxyamphetamine (MDA) (alpha-methyl-1,3-benzodioxole-5-ethanamine)(5) 2,5-dimethoxyamphetamine (2,5-dimethoxy-alpha-methylbenzene-ethanamine)(6) 4-methoxyamphetamine (4-methoxy-alpha-methylbenzene­ethanamine)(7) 2,4,5-trimethoxyamphetamine (2,4,5-trimethoxy-alpha-methylbenzene­ethanamine)(8) N-methyl-3,4-methylenedioxy-amphetamine (MDMA) (N,alpha-dimethyl-1,3-benzodioxole-5-ethanamine)(9) 4-ethoxy-2,5-dimethoxyamphetamine (4-ethoxy-2,5-dimethoxy-alpha-methylbenzeneethanamine)(10) 5-methoxy-3,4-methylenedioxy- amphetamine (7-methoxy-alpha-methyl-1,3-benzo­dioxole-5-ethanamine)(11) N,N-dimethyl-3,4-methylenedioxyamphetamine (N,N, alpha-trimethyl-1,3-benzodioxole-5-ethanamine)(12) N-ethyl-3,4-methylenedioxyamphetamine (N-ethyl-alpha-methyl-1,3-benzo­dioxole-5-ethanamine)(13) 4-ethyl-2,5-dimethoxyamphetamine (DOET) (4-ethyl-2,5-dimethoxy-alpha-methylbenzeneethanamine)(14) 4-bromo-2,5-dimethoxyamphetamine (4-bromo-2,5-dimethoxy-alpha-methylbenzeneethanamine)(15) 4-chloro-2,5-dimethoxyamphetamine (4-chloro-2,5-dimethoxy-alpha-methyl-benzeneethanamine)(16) 4-ethoxyamphetamine (4-ethoxy-alpha-methylbenzene­ethanamine)(17) Benzphetamine (N-benzyl-N,alpha-dimethylbenzene­ethanamine)(18) N-Propyl-3,4-methylenedioxy- amphetamine (alpha-methyl-N-propyl-1,3-benzo­dioxole-5-ethanamine)(19) N-(2-Hydroxyethyl)-alpha-meth-ylbenzene­ethanamine(20) N-hydroxy-3,4-methylenedioxy- amphetamine (N-[alpha-methyl-3,4-(methylenedioxy)phenethyl]hydroxyla­mine)(21) 3,4,5-trimethoxyamphetamine (3,4,5-trimethoxy-alpha-methylbenzene­ethanamine)20 Flunitrazepam (5-(o-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one) and any of its salts or derivatives21 4-hydroxybutanoic acid (GHB) and any of its salts22 Tapentadol (3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-phenol), its salts, derivatives and isomers and salts of derivatives and isomers23 AH-7921 (1-(3,4-dichlorobenzamidomethyl)cyclohexyldimethylamine), its salts, isomers and salts of isomers24 MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine), its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues, including(1) Diphenidine (DEP) (1-(1,2-diphenylethyl)piperidine)(2) Methoxphenidine (2-MeO-Diphenidine, MXP) (1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine)(3) Ephenidine (NEDPA, EPE) (N-ethyl-1,2-diphenylethylamine)(4) Isophenidine (NPDPA) (N-isopropyl-1,2-diphenylethylamine)but not including(5) Lefetamine ((-)-N,N-dimethyl-alpha-phenylbenzeneethanamine), its salts, derivatives and isomers and salts of derivatives and isomers25 W-18 (4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]benzenesulfonamide), its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues26 U-47700 (3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide), its salts, derivatives, isomers and analogues, and salts of derivatives, isomers and analogues, including(1) Bromadoline (4-bromo-N-(2-(dimethylamino)cyclohexyl)benzamide)(2) U-47109 (3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)benzamide)(3) U-48520 (4-chloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide)(4) U-50211 (N-(2-(dimethylamino)cyclohexyl)-4-hydroxy-N-methylbenzamide)(5) U-77891 (3,4-dibromo-N-methyl-N-(1-methyl-1-azaspiro[4.5]decan-6-yl)benzamide)27 Tramadol (2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol), its salts, isomers and salts of isomers and the following derivatives of tramadol and the salts, isomers and salts of isomers of those derivatives:(1) O-desmethyltramadol (3-[2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]-phenol)(2) N,O-didesmethyltramadol (3-[1-hydroxy-2-[(methylamino)methyl]cyclohexyl]-phenol)28 AP-237 (1-(4-cinnamylpiperazin-1-yl)butan-1-one), its salts, derivatives and analogues and salts of derivatives and analogues, including:(1) 2-methyl-AP-237 (1-(4-cinnamyl-2-methylpiperazin-1-yl)butan-1-one)(2) para-methyl-AP-237 ((E)-1-(4-(3-(p-tolyl)allyl)piperazin-1-yl)butan-1-one)(3) AP-238 (1-(4-cinnamyl-2,6-dimethylpiperazin-1-yl)propan-1-one)

Schedule II · (Sections 2, 4 to 7.1, 10, 29, 55 and 60)

1 [Repealed, 2018, c. 16, s. 204]2 Synthetic cannabinoid receptor type 1 agonists, their salts, derivatives, isomers, and salts of derivatives and isomers — with the exception of any substance that is identical to any phytocannabinoid and with the exception of ((3S)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl)-1-naphthalenyl-methanone (WIN 55,212-3) and its salts — including those that fall within the following core chemical structure classes:(1) Any substance that has a 2-(cyclohexyl)phenol structure with substitution at the 1-position of the benzene ring by a hydroxy, ether or ester group and further substituted at the 5-position of the benzene ring, whether or not further substituted on the benzene ring to any extent, and substituted at the 3’-position of the cyclohexyl ring by an alkyl, carbonyl, hydroxyl, ether or ester, and whether or not further substituted on the cyclohexyl ring to any extent, including(i) Nabilone ((±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one)(ii) Parahexyl (3-hexyl-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-1-ol)(iii) 3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol (DMHP)(iv) 5-(1,1-dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)phenol (CP 55,940)(v) 5-(1,1-dimethylheptyl)-2-(3-hydroxycyclohexyl)phenol (CP 47,497)(2) Any substance that has a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent, including(i) 1-pentyl-3-(1-naphthoyl)indole (JWH-018)(ii) 1-butyl-3-(1-naphthoyl)indole (JWH-073)(iii) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)(iv) 1-hexyl-3-(1-naphthoyl)indole (JWH-019)(v) 1-(4-pentenyl)-3-(1-naphthoyl)indole (JWH-022)(vi) 1-butyl-3-(4-methoxy-1-naphthoyl)indole (JWH-080)(vii) 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081)(viii) 1-(2-morpholin-4-ylethyl)-3-(1-naphthoyl)indole (JWH-200)(ix) 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210)(x) 1-pentyl-3-(2-methoxy-1-naphthoyl)indole (JWH-267)(xi) 1-[(N-methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole (AM-1220)(xii) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201)(xiii) 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole (MAM-2201)(xiv) 1-(5-fluoropentyl)-3-(4-ethyl-1-naphthoyl)indole (EAM-2201)(xv) ((3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl)-1-naphthalenyl-methanone (WIN 55,212-2)(3) Any substance that has a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted on the pyrrole ring to any extent and whether or not substituted on the naphthyl ring to any extent, including(i) 1-pentyl-5-(2-fluorophenyl)-3-(1-naphthoyl)pyrrole (JWH-307)(4) Any substance that has a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the phenyl ring to any extent, including(i) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)(ii) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251)(iii) 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302)(5) Any substance that has a 3-benzoylindole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the phenyl ring to any extent, including(i) 1-(1-methylpiperidin-2-ylmethyl)-3-(2-iodobenzoyl)indole (AM-2233)(6) Any substance that has a 3-methanone(cyclopropyl)indole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the cyclopropyl ring to any extent, including(i) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (UR-144)(ii) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (5F-UR-144)(iii) (1-(2-(4-morpholinyl)ethyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (A-796,260)(7) Any substance that has a quinolin-8-yl 1H-indole-3-carboxylate structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the quinolin-8-yl ring to any extent, including(i) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22)(ii) 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (5F-PB-22)(8) Any substance that has a 3-carboxamideindazole structure with substitution at the nitrogen atom of the indazole ring, whether or not further substituted on the indazole ring to any extent and whether or not substituted at the carboxamide group to any extent, including(i) N-(adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide (AKB48)(ii) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-AKB48)(iii) N-(1-(aminocarbonyl)-2-methylpropyl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA)(iv) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA)(9) Any substance that has a 3-carboxamideindole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted at the carboxamide group to any extent, including(i) N-(adamantan-1-yl)-1-fluoropentylindole-3-carboxamide (STS-135)(ii) N-(adamantan-1-yl)-1-pentylindole-3-carboxamide (APICA)

Schedule III · (Sections 2, 4 to 7.1, 10, 29, 55 and 60)

1 [Repealed, 2012, c. 1, s. 45]2 Methylphenidate (methyl 2-phenyl-2-(piperidin-2-yl)acetate), its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues, including(1) Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate)(2) Isopropylphenidate (isopropyl 2-phenyl-2-(piperidin-2-yl)acetate)(3) Propylphenidate (propyl 2-phenyl-2-(piperidin-2-yl)acetate)(4) 3,4-Dichloromethylphenidate (methyl 2-(3,4-dichlorophenyl)-2-(piperidin-2-yl)acetate)(5) 4-Methylmethylphenidate (methyl 2-(4-methylphenyl)-2-(piperidin-2-yl)acetate)(6) 4-Fluoromethylphenidate (methyl 2-(4-fluorophenyl)-2-(piperidin-2-yl)acetate)(7) Methylnaphthidate (methyl 2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate)(8) Ethylnaphthidate (ethyl 2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate)3 Methaqualone (2–methyl–3–(2–methylphenyl)–4(3H)–quinazolinone) and any salt thereof4 Mecloqualone (2–methyl–3–(2–chlorophenyl)–4(3H)–quinazolinone) and any salt thereof5 Lysergic acid diethylamide (LSD) (N,N–diethyllysergamide) and any salt thereof6 N,N–Diethyltryptamine (DET) (3–[(2–diethylamino) ethyl]indole) and any salt thereof7 N,N–Dimethyltryptamine (DMT) (3–[(2–dimethylamino) ethyl]indole) and any salt thereof8 N–Methyl–3–piperidyl benzilate (LBJ) (3–[(hydroxydiphenylacetyl)oxy]–1–methylpiperidine) and any salt thereof9 Harmaline (4,9–dihydro–7–methoxy–1–methyl–3H–pyrido(3,4–b)indole) and any salt thereof10 Harmalol (4,9–dihydro–1–methyl–3H–pyrido(3,4–b)indol–7–ol) and any salt thereof11 Psilocin (3–[2–(dimethylamino)ethyl]–4–hydroxyindole) and any salt thereof12 Psilocybin (3–[2–(dimethylamino)ethyl]–4–phosphoryloxyindole) and any salt thereof13 N–(1–phenylcyclohexyl)ethylamine (PCE) and any salt thereof14 1–[1–(2–Thienyl) cyclohexyl]piperidine (TCP) and any salt thereof15 1–Phenyl–N–propylcyclohexanamine and any salt thereof16 Rolicyclidine (1-(1-phenylcyclohexyl) pyrrolidine) and any salt thereof17 Mescaline (3,4,5–trimethoxybenzeneethanamine) and any salt thereof, but not peyote (lophophora)18 [Repealed, SOR/2017-249, s. 1]19 Cathinone ((-)-alpha-aminopropiophenone) and its salts20 Fenetylline (d,l–3,7–dihydro–1,3–dimethyl–7–(2–[(1–methyl–2–phenethyl)amino]ethyl)–1H–purine–2, 6–dione) and any salt thereof21 2–Methylamino–1–phenyl–1–propanone and any salt thereof22 1–[1–(Phenylmethyl)cyclohexyl]piperidine and any salt thereof23 1–[1–(4–Methylphenyl)cyclohexyl]piperidine and any salt thereof24 [Repealed, SOR/2016-73, s. 1]25 and 26 [Repealed, 2012, c. 1, s. 46]27 Aminorex (5-phenyl-4,5-dihydro-1,3-oxazol-2-amine), its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues, including(1) 4-Methylaminorex (4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine)(2) 4,4’-Dimethylaminorex (4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine)28 Etryptamine (3-(2-aminobutyl)indole) and any salt thereof29 Lefetamine ((-)-N,N-dimethyl-alpha-phenylbenzeneethanamine), its salts, derivatives and isomers and salts of derivatives and isomers30 Mesocarb (3-(alpha-methylphenethyl)-N-(phenylcarbamoyl)sydnone imine) and any salt thereof31 Zipeprol (4-(2-methoxy-2-phenylethyl)-alpha-(methoxyphenylmethyl)-1-piperazineethanol) and any salt thereof32 Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid) and any salt thereof33 Benzylpiperazine (BZP), namely 1-benzylpiperazine and its salts, isomers and salts of isomers34 Trifluoromethylphenylpiperazine (TFMPP), namely 1-(3-trifluoromethylphenyl)piperazine and its salts, isomers and salts of isomers35 2C-phenethylamines and their salts, derivatives, isomers and salts of derivatives and isomers that correspond to the following chemical description :any substance that has a 1-amino-2-phenylethane structure substituted at the 2’ and 5’ or 2’ and 6’ positions of the benzene ring by an alkoxy or haloalkoxy group, or substituted at two adjacent carbon atoms of the benzene ring which results in the formation of a furan, dihydrofuran, pyran, dihydropyran or methylenedioxy group — whether or not further substituted on the benzene ring to any extent, whether or not substituted at the amino group by one or two, or a combination of, methyl, ethyl, propyl, isopropyl, hydroxyl, benzyl (or benzyl substituted to any extent) or benzylene (or benzylene substituted to any extent) groups and whether or not substituted at the 2-ethyl (beta carbon) position by a hydroxyl, oxo or alkoxy group — and its salts and derivatives and salts of derivatives, including(1) 4-bromo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25B-NBOMe)(2) 4-chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25C-NBOMe)(3) 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe)(4) 4-bromo-2,5-dimethoxybenzeneethanamine (2C-B)

Schedule IV · (Sections 2, 4 to 7.1, 10, 29, 55 and 60)

1 Barbiturates, their salts and derivatives including(1) Allobarbital (5,5–diallylbarbituric acid)(2) Alphenal (5–allyl–5–phenylbarbituric acid)(3) Amobarbital (5–ethyl–5–(3–methylbutyl)barbituric acid)(4) Aprobarbital (5–allyl–5–isopropylbarbituric acid)(5) Barbital (5,5–diethylbarbituric acid)(6) [Repealed, SOR/2017-13, s. 7](7) Butabarbital (5–sec–butyl–5–ethylbarbituric acid)(8) Butalbital (5–allyl–5–isobutylbarbituric acid)(9) Butallylonal (5–(2–bromoallyl)–5–sec–butylbarbituric acid)(10) Butethal (5–butyl–5–ethylbarbituric acid)(11) Cyclobarbital (5–(1–cyclohexen–1–yl)–5–ethylbarbituric acid)(12) Cyclopal (5–allyl–5–(2–cyclopenten–1–yl)barbituric acid)(13) Heptabarbital (5–(1–cyclohepten–1–yl)–5–ethylbarbituric acid)(14) Hexethal (5–ethyl–5–hexylbarbituric acid)(15) Hexobarbital (5–(1–cyclohexen–1–yl)–1,5–dimethylbarbituric acid)(16) Mephobarbital (5–ethyl–1–methyl–5–phenylbarbituric acid)(17) Methabarbital (5,5–diethyl–1–methylbarbituric acid)(18) [Repealed, SOR/2025-243, s. 10](19) Propallylonal (5–(2–bromoallyl)–5–isopropylbarbituric acid)(20) Pentobarbital (5–ethyl–5–(1–methylbutyl)barbituric acid)(21) Phenobarbital (5–ethyl–5–phenylbarbituric acid)(22) Probarbital (5–ethyl–5–isopropylbarbituric acid)(23) Phenylmethylbarbituric Acid (5–methyl–5–phenylbarbituric acid)(24) Secobarbital (5–allyl–5–(1–methylbutyl)barbituric acid)(25) Sigmodal (5–(2–bromoallyl)–5–(1–methylbutyl) barbituric acid)(26) Talbutal (5–allyl–5–sec–butylbarbituric acid)(27) Vinbarbital (5–ethyl–5–(1–methyl–1–butenyl)barbituric acid)(28) Vinylbital (5–(1–methylbutyl)–5–vinylbarbituric acid)but not including(29) Barbituric Acid (2,4,6(1H,3H,5H)-pyrimidinetrione) and its salts(30) 1,3-dimethylbarbituric acid (1,3-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione) and its salts2 Thiobarbiturates, their salts and derivatives including:(1) Thialbarbital (5–allyl–5–(2–cyclohexen–1–yl)–2–thiobarbituric acid)(2) Thiamylal (5–allyl–5–(1–methylbutyl)–2–thiobarbituric acid)(3) Thiobarbituric Acid (2–thiobarbituric acid)(4) Thiopental (5–ethyl–5–(1–methylbutyl)–2–thiobarbituric acid)3 Chlorphentermine (1–(p–chlorophenyl)–2–methyl–2–aminopropane) and any salt thereof4 Diethylpropion (2–(diethylamino)propiophenone) and any salt thereof5 Phendimetrazine (d–3,4–dimethyl–2–phenylmorpholine) and any salt thereof6 Phenmetrazine (3–methyl–2–phenylmorpholine) and any salt thereof7 Pipradrol (alpha,alpha-diphenyl-2-piperidinemethanol) and its salts8 Phentermine (alpha,alpha–dimethylbenzeneethanamine) and any salt thereof9 Butorphanol (l-N-cyclobutylmethyl-3,14-dihydroxymorphinan) and its salts10 Nalbuphine (N-cyclobutylmethyl-4,5-epoxy-morphinan-3,6,14-triol) and its salts11 Glutethimide (2–ethyl–2–phenylglutarimide)12 Clotiazepam (5–(o–chlorophenyl)–7–ethyl–1,3–dihydro–1–methyl–2H–thieno[2,3–e]–1,4–diazepin–2–one) and any salt thereof13 Ethchlorvynol (ethyl–2–chlorovinyl ethynyl carbinol)14 Ethinamate (1–ethynylcyclohexanol carbamate)15 Mazindol (5–(p–chlorophenyl)–2,5–dihydro–3H–imidazo[2,1–a]isoindol–5–ol)16 Meprobamate (2–methyl–2–propyl–1,3–propanediol dicarbamate)17 Methyprylon (3,3–diethyl–5–methyl–2,4–piperidinedione)18 Benzodiazepines, their salts and derivatives, including:(1) Alprazolam (8–chloro–1–methyl–6–phenyl–4H–s–triazolo[4,3–a][1,4] benzodiazepine)(2) Bromazepam (7–bromo–1,3–dihydro–5–(2–pyridyl)–2H–1, 4–benzodiazepin–2–one)(2.1) Brotizolam (2-bromo-4-(o-chlorophenyl)-9-methyl-6H-thieno[3,2-f]-s-triazolo[4,3-a][1,4]diazepine)(3) Camazepam (7–chloro–1,3–dihydro–3–(N,N– dimethylcarbamoyl)–1–methyl–5–phenyl–2H–1, 4–benzodiazepin–2–one)(4) Chlordiazepoxide (7–chloro–2–(methylamino)–5–phenyl–3H–1,4–benzodiazepine–4–oxide)(5) Clobazam (7–chloro–1–methyl–5–phenyl–1H–1,5–benzodiazepine–2,4(3H,5H)–dione)(6) Clonazepam (5–(o–chlorophenyl)–1,3–dihydro–7–nitro–2H–1,4–benzodiazepin–2–one)(7) Clorazepate (7–chloro–2,3–dihydro–2,2–dihydroxy–5–phenyl–1H–1,4–benzodiazepine–3–carboxylic acid)(8) Cloxazolam (10–chloro–11b–(o–chlorophenyl)–2,3, 7,11b–tetrahydrooxazolo[3,2–d][1,4]benzodiazepin 6–(5H)–one)(9) Delorazepam (7–chloro–5–(o–chlorophenyl)–1,3–dihydro–2H–1,4–benzodiazepin–2–one)(10) Diazepam (7–chloro–1,3–dihydro–1–methyl–5–phenyl–2H–1,4–benzodiazepin–2–one)(11) Estazolam (8–chloro–6–phenyl–4H–s–triazolo [4,3–a][1,4]benzodiazepine)(12) Ethyl Loflazepate (ethyl 7–chloro–5–(o–fluorophenyl)–2,3–dihydro–2–oxo–1H–1,4–benzodiazepine–3–carboxylate)(13) Fludiazepam (7–chloro–5–(o–fluorophenyl)–1,3–dihydro–1–methyl–2H–1,4–benzodiazepin–2–one)(14) [Repealed, SOR/98-173, s. 2](15) Flurazepam (7–chloro–1–[2–(diethylamino) ethyl]–5–(o–fluorophenyl)–1,3–dihydro–2H–1,4–benzodiazepin–2–one)(16) Halazepam (7–chloro–1,3–dihydro–5–phenyl–1–(2,2,2–trifluoroethyl)–2H–1,4–benzodiazepin–2–one)(17) Haloxazolam (10–bromo–11b–(o–fluorophenyl)–2,3,7,11b–tetrahydrooxazolo[3,2–d][1,4]benzodiazepin–6(5H)–one)(18) Ketazolam (11–chloro–8,12b–dihydro–2,8–dimethyl–12b–phenyl–4H–[1,3]–oxazino–[3,2–d][1,4] benzodiazepine–4,7(6H)–dione)(19) Loprazolam (6–(o–chlorophenyl)–2,4–dihydro–2–[(4–methyl–1–piperazinyl)methylene]–8–nitro–1H–imidazo[1,2–a][1,4]benzodiazepin–1–one)(20) Lorazepam (7–chloro–5–(o–chlorophenyl)–1,3–dihydro–3–hydroxy–2H–1,4–benzodiazepin–2–one)(21) Lormetazepam (7–chloro–5–(o–chlorophenyl)–1,3–dihydro–3–hydroxy–1–methyl–2H–1,4–benzodiazepin–2–one)(22) Medazepam (7–chloro–2,3–dihydro–1–methyl–5–phenyl–1H–1,4–benzodiazepine)(22.1) Midazolam (8-chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine)(23) Nimetazepam (1,3–dihydro–1–methyl–7–nitro–5–phenyl–2H–1,4–benzodiazepin–2–one)(24) Nitrazepam (1,3–dihydro–7–nitro–5–phenyl–2H–1,4–benzodiazepin–2–one)(25) Nordazepam (7–chloro–1,3–dihydro–5–phenyl–2H–1,4–benzodiazepin–2–one)(26) Oxazepam (7–chloro–1,3–dihydro–3–hydroxy–5–phenyl–2H–1,4–benzodiazepin–2–one)(27) Oxazolam (10–chloro–2,3,7,11b–tetrahydro–2–methyl–11b–phenyloxazolo[3,2–d] [1,4]benzodiazepin–6(5H)–one)(28) Pinazepam (7–chloro–1,3–dihydro–5–phenyl–1–(2–propynyl)–2H–1,4–benzodiazepin–2–one)(29) Prazepam (7–chloro–1–(cyclopropylmethyl)–1, 3–dihydro–5–phenyl–2H–1,4–benzodiazepin–2–one)(29.1) Quazepam (7-chloro-5-(o-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione)(30) Temazepam (7–chloro–1,3–dihydro–3–hydroxy–1–methyl–5–phenyl–2H–1,4–benzodiazepin–2–one)(31) Tetrazepam (7–chloro–5–(cyclohexen–1–yl)–1,3–dihydro–1–methyl–2H–1,4–benzodiazepin–2–one)(32) Triazolam (8–chloro–6–(o–chlorophenyl)–1–methyl–4H–s–triazolo[4,3–a][1,4]benzodiazepine)but not including:(32.1) Clozapine (8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine) and any salt thereof(33) Flunitrazepam (5-(o-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one) and any salts or derivatives thereof(34) Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine) and its salts(35) Clozapine N-oxide (8-chloro-11-(4-methyl-4-oxido-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine) and its salts19 Catha edulis Forsk, its preparations, derivatives, alkaloids and salts, including:(1) Cathine (d–threo–2–amino–1–hydroxy–1–phenylpropane)20 Fencamfamin (d,l–N–ethyl–3–phenylbicyclo[2,2,1] heptan–2–amine) and any salt thereof21 Fenproporex (d,l–3–[(alpha–methylphenethyl)amino]propionitrile) and any salt thereof22 Mefenorex (d,l–N–(3–chloropropyl)–alpha–methylbenzeneethanamine) and any salt thereof23 Anabolic steroids and their derivatives including:(1) Androisoxazole (17beta–hydroxy–17alpha–methylandrostano [3,2–c]isoxazole)(2) Androstanolone (17beta–hydroxy–5alpha–androstan–3–one)(3) Androstenediol (androst–5–ene–3beta,17beta–diol)(4) Bolandiol (estr–4–ene–3beta,17beta–diol)(5) Bolasterone (17beta–hydroxy–7alpha,17–dimethylandrost–4–en–3–one)(6) Bolazine (17beta–hydroxy–2alpha–methyl–5alpha–androstan–3–one azine)(7) Boldenone (17beta–hydroxyandrosta–1,4–dien–3–one)(8) Bolenol (19–nor–17alpha–pregn–5–en–17–ol)(9) Calusterone (17beta–hydroxy–7beta,17–dimethylandrost–4–en–3–one)(10) Clostebol (4–chloro–17beta–hydroxyandrost–4–en–3–one)(11) Drostanolone (17beta–hydroxy–2alpha–methyl–5alpha–androstan–3–one)(12) Enestebol (4, 17beta–dihydroxy–17–methylandrosta–1,4–dien–3–one)(13) Epitiostanol (2alpha, 3alpha–epithio–5alpha–androstan–17beta–ol)(14) Ethylestrenol (19–nor–17alpha–pregn–4–en–17–ol)(15) [Repealed, SOR/2025-243, s. 11](16) Fluoxymesterone (9–fluoro–11beta,17beta–dihydroxy–17–methylandrost–4–en–3–one)(17) Formebolone (11alpha, 17beta–dihydroxy–17–methyl–3–oxoandrosta–1,4 di–en–2–carboxaldehyde)(18) Furazabol (17–methyl–5alpha–androstano[2,3–c] furazan–17beta–ol)(19) Mebolazine (17beta–hydroxy–2alpha,17–dimethyl–5alpha–androstan–3–one azine)(20) Mesabolone (17beta–[(1–methoxycyclohexyl)oxy]–5alpha–androst–1–en–3–one)(21) Mesterolone (17beta–hydroxy–1alpha–methyl–5alpha–androstan–3–one)(22) Metandienone (17beta–hydroxy–17–methylandrosta–1,4–dien–3–one)(23) Metenolone (17beta–hydroxy–1–methyl–5alpha–androst–1–en–3–one)(24) Methandriol (17alpha–methylandrost–5–ene–3beta,17beta–diol)(25) Methyltestosterone (17beta–hydroxy–17–methylandrost–4–en–3–one)(26) Metribolone (17beta–hydroxy–17–methylestra–4, 9,11–trien–3–one)(27) Mibolerone (17beta–hydroxy–7alpha,17–dimethylestr–4–en–3–one)(28) Nandrolone (17beta–hydroxyestr–4–en–3–one)(29) Norboletone (13–ethyl–17beta–hydroxy–18, 19–dinorpregn–4–en–3–one)(30) Norclostebol (4–chloro–17beta–hydroxyestr–4–en–3–one)(31) Norethandrolone (17alpha–ethyl–17beta–hydroxyestr–4–en–3–one)(32) Oxabolone (4,17beta–dihydroxyestr–4–en–3–one)(33) Oxandrolone (17beta–hydroxy–17–methyl–2–oxa–5alpha–androstan–3–one)(34) Oxymesterone (4,17beta–dihydroxy–17–methylandrost–4–en–3–one)(35) Oxymetholone (17beta–hydroxy–2–(hydroxymethylene)–17–methyl–5alpha–androstan–3–one)(36) Prasterone (3beta–hydroxyandrost–5–en–17–one)(37) Quinbolone (17beta–(1–cyclopenten–1–yloxy) androsta–1,4–dien–3–one)(38) Stanozolol (17beta–hydroxy–17–methyl–5alpha–androstano [3,2–c]pyrazole)(39) Stenbolone (17beta–hydroxy–2–methyl–5alpha–androst–1–en–3–one)(40) Testosterone (17beta–hydroxyandrost–4–en–3–one)(41) Tibolone ((7alpha,17alpha)-17–hydroxy–7–methyl–19–norpregn–5(10) en–20–yn–3–one)(42) Tiomesterone (1alpha,7alpha–bis(acetylthio)–17beta –hydroxy–17–methylandrost–4–en–3–one)(43) Trenbolone (17beta–hydroxyestra–4,9,11–trien–3–one)24 Zeranol (3,4,5,6,7,8,9,10,11,12–decahydro–7,14,16– trihydroxy–3–methyl–1H–2–benzoxacyclotetradecin–1–one)25 Zolpidem (N,N,6-trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide) and any salt thereof25.1 Pemoline (2-amino-5-phenyl-oxazolin-4-one) and any salt thereof26 Pyrovalerone (4′-methyl-2-(1-pyrrolidinyl)valerophenone) and any salt thereof27 Salvia divinorum (S. divinorum), its preparations and derivatives, including:(1) Salvinorin A ((2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic acid methyl ester)28 Carisoprodol (2-((carbamoyloxy)methyl)-2-methylpentyl isopropylcarbamate)

Schedule V · (Sections 2, 5 to 7.1, 10, 55, 60.1 and 60.2)

Controlled Substances | Column 1 | Column 2Item | Substance | Period1 | Spirobrorphine (8-[1-(4-bromophenyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one) and its salts | June 5, 2026 to June 4, 20272 | Spirochlorphine (8-[1-(4-chlorophenyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one) and its salts | June 5, 2026 to June 4, 2027Precursors | Column 1 | Column 2Item | Substance | Period1 | R 29676 (5-chloro-1-(piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one) and its salts | June 5, 2026 to June 4, 20272 | [Repealed, 1996, c. 19, s. 60.1] | | Column 1 | Column 2Item | Substance | Period1 | [Repealed, 1996, c. 19, s. 60.1] | | Column 1 | Column 2Item | Substance | Period1 | Any preparation or mixture that contains R 29676 (5-chloro-1-(piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one) or its salts | June 5, 2026 to June 4, 20272 | [Repealed, 1996, c. 19, s. 60.1] | 3 | [Repealed, 1996, c. 19, s. 60.1] |

Schedule VI · (Sections 2, 6, 55 and 60)

Class A Precursors1 Acetic anhydride2 N-Acetylanthranilic acid (2-acetamidobenzoic acid) and its salts3 Anthranilic acid (2-aminobenzoic acid) and its salts4 Ephedrine (erythro-2-(methylamino)-1-phenylpropan-1-ol), its salts and any plant containing ephedrine or any of its salts5 Ergometrine (9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8-carboxamide) and its salts6 Ergotamine (12′-hydroxy-2′-methyl-5′-(phenylmethyl)ergotaman-3′,6′,18-trione) and its salts7 Isosafrole (5-(1-propenyl)-1,3-benzodioxole)8 Lysergic acid (9,10-didehydro-6-methylergoline-8-carboxylic acid) and its salts9 3,4-Methylenedioxyphenyl-2-propanone (1-(1,3-benzodioxole)-2-propanone), its derivatives and analogues and salts of derivatives and analogues, including:(1) methyl 3-(1,3 benzodioxol-5-yl)-2-methyloxirane-2-carboxylate (MMDMG)10 Norephedrine (Phenylpropanolamine) and its salts11 1-Phenyl-2-propanone, its derivatives and analogues and salts of derivatives and analogues, including:(1) methyl 2-methyl-3-phenyloxirane-2-carboxylate (BMK methyl glycidate)(2) 3-oxo-2-phenylbutanamide (alpha- phenylacetoacetamide-APAA)12 Phenylacetic acid and its salts13 Piperidine and its salts14 Piperonal (1,3-benzodioxole-5-carboxaldehyde)15 Potassium permanganate16 Pseudoephedrine (threo-2-(methylamino)-1-phenylpropan-1-ol), its salts and any plant containing pseudoephedrine or any of its salts17 Safrole (5-(2-propenyl)-1,3-benzodioxole) and any essential oil containing more than 4% safrole18 Gamma-butyrolactone (dihydro-2(3H)-furanone)19 1,4-butanediol20 Red Phosphorus21 White Phosphorus22 Hypophosphorous acid, its salts and derivatives23 Hydriodic acid24 Alpha-phenylacetoacetonitrile and its salts, isomers and salts of isomers25 Propionyl chloride26 1-Phenethyl-4-piperidone and its salts27 4-Piperidone (piperidin-4-one), its salts, derivatives and analogues and salts of derivatives and analogues, including:(1) 1-boc-4-piperidone (tert-butyl 4-oxopiperidine-1-carboxylate)(2) 3-methyl-4-piperidone (3-methylpiperidin-4-one)(3) 1-benzyl-4-piperidone (1-benzylpiperidin-4-one)28 Norfentanyl (N-phenyl-N-piperidin-4-ylpropanamide), its salts, derivatives and analogues and salts of derivatives and analogues29 1-Phenethylpiperidin-4-ylidenephenylamine and its salts30 N-Phenyl-4-piperidinamine (N-phenylpiperidin-4-amine), its salts, derivatives and analogues and salts of derivatives and analogues, including:(1) 4-anilino-1-boc-piperidine (tert-butyl 4-(phenylamino)piperidine-1-carboxylate)(2) 4-fluoro anilino-1-boc-piperidine (tert-butyl 4-((4-fluorophenyl)amino)piperidine-1-carboxylate)(3) N-(4-fluorophenyl)-4-piperidinamine (N-(4-fluorophenyl)piperidin-4-amine)(4) 4-bromo anilino-1-boc-piperidine (tert-butyl 4-((4-bromophenyl)amino)piperidine-1-carboxylate)31 N¹,N¹,N²-trimethylcyclohexane-1,2-diamine and its salts32 Benzylfentanyl (N-(1-benzylpiperidin-4-yl)-N-phenylpropionamide), its salts, derivatives and analogues and salts of derivatives and analogues33 Phenethyl bromide ((2-bromoethyl)benzene)34 Propionic anhydride (propanoic anhydride)35 Phenethyl iodide ((2-iodoethyl)benzene)36 Phenethyl chloride ((2-chloroethyl)benzene)^noteClass B Precursors1 Acetone2 Ethyl ether3 Hydrochloric acid4 Methyl ethyl ketone5 Sulphuric acid6 Toluene7 Benzyl chloride ((chloromethyl)benzene)^notePreparations and Mixtures1 Any preparation or mixture that contains a precursor set out in Part 1, except items 20 to 23, or in Part 2.

Schedule VII

Schedule VIII

Schedule IX · (Sections 2 and 60)

1 Manual, semi-automatic or fully automatic device — unassembled or fully or partially assembled or disassembled — that may be used to compact or mould powdered, granular or semi-solid material to produce coherent solid tablets2 Manual, semi-automatic or fully automatic device — unassembled or fully or partially assembled or disassembled — that may be used to fill capsules with any powdered, granular, semi-solid or liquid material3 Die that is suitable for use in, but not already part of, a device referred to in item 1 or 24 Mould that is suitable for use in, but not already part of, a device referred to in item 1 or 25 Punch that is suitable for use in, but not already part of, a device referred to in item 1 or 2

Related provisions

— 2022, c. 15, s. 21On the fourth anniversary of the day on which this Act comes into force, a comprehensive review of the provisions and operation of the Act is to be undertaken by the standing committee of each House that normally considers matters relating to justice. — 2022, c. 17, s. 76For greater certainty, but subject to sections 77 and 78, the amendments made by this Act also apply with respect to proceedings that are ongoing on the day on which this Act comes into force. — 2022, c. 17, s. 78.1The Minister of Justice must, no later than three years after the day on which this Act receives royal assent, initiate one or more independent reviews on the use of remote proceedings in criminal justice matters that must include an assessment of whether remote proceedingsenhance, preserve or adversely affect access to justice;maintain fundamental principles of the administration of justice; andadequately address the rights and obligations of participants in the criminal justice system, including accused persons.The Minister of Justice must, no later than five years after the day on which a review is initiated, cause a report on the review — including any findings or recommendations resulting from it — to be laid before each House of Parliament. — 2022, c. 17, s. 78.2At the start of the fifth year after the day on which this Act receives royal assent, the provisions enacted or amended by this Act are to be referred to a committee of the Senate and a committee of the House of Commons that may be designated or established for the purpose of reviewing the provisions.The committees to which the provisions are referred are to review them and the use of remote proceedings in criminal justice matters and submit reports to the Houses of Parliament of which they are committees, including statements setting out any changes to the provisions that they recommend. — 2024, c. 17, s. 416The following definitions apply in this section and sections 417 to 419.commencement day means the day on which subsection 413(4) and sections 414 and 415 come into force. (date de référence)previous version means the Controlled Drugs and Substances Act, as it reads immediately before commencement day. (version antérieure)regulatory scheme means regulations that are made under subsection 55(1) of the Controlled Drugs and Substances Act, as it reads on the day on which this section comes into force, respecting authorizations for activities that could be allowed under an exemption granted under subsection 56.1(1) of the previous version. (régime réglementaire) — 2024, c. 17, s. 417An exemption granted under subsection 56.1(1) of the previous version that is valid immediately before commencement day is deemed to be an authorization issued under the regulatory scheme on that day.Subsection (1) does not have the effect of extending the validity period of the exemption.For greater certainty, the terms and conditions of the exemption are terms and conditions of the authorization. However, if there is a conflict between any of those terms and conditions and a requirement of the regulatory scheme, the requirement of the regulatory scheme prevails to the extent of the conflict. — 2024, c. 17, s. 418If an application for an exemption under subsection 56.1(1) of the previous version is submitted before commencement day and the minister responsible for the previous version has not, before that day, made a decision in relation to the application, the application is deemed to have been submitted on that day as an application for an authorization under the regulatory scheme. — 2024, c. 17, s. 419The Governor in Council may make any regulations that the Governor in Council considers necessary to provide for any other transitional matter arising from the coming into force of the regulatory scheme.

Amendments not in force

— 2017, c. 7, s. 1(1)The definition adjudicator in subsection 2(1) of the Controlled Drugs and Substances Act is repealed. — 2017, c. 7, s. 28Part V of the Act is replaced by the following :Administrative Monetary PenaltiesViolationEvery person who contravenes a provision designated by regulations made under paragraph 34(1)(a), or contravenes an order made under section 45.1 or 45.2 or reviewed under section 45.4, commits a violation and is liable to the penalty established in accordance with the provisions of this Act and the regulations.Powers of the Governor in Council and the MinisterThe Governor in Council may make regulationsdesignating as a violation that may be proceeded with in accordance with this Act the contravention of any specified provision of this Act — except a provision of Part I — or the regulations;fixing a penalty, or a range of penalties, in respect of each violation;classifying each violation as a minor violation, a serious violation or a very serious violation; andrespecting the circumstances under which, the criteria by which and the manner in which a penalty may be increased or reduced, including a reduction in the amount that is provided for in a compliance agreement.The maximum penalty for a violation is $30,000.Unless a penalty is fixed under paragraph 34(1)(b), the amount of a penalty shall, in each case, be determined taking into accountthe history of compliance with the provisions of this Act or the regulations by the person who committed the violation;the harm to public health or safety that resulted or could have resulted from the violation;whether the person made reasonable efforts to mitigate or reverse the violation’s effects;whether the person derived any competitive or economic benefit from the violation; andany other prescribed criteria.The Minister maydesignate individuals, or classes of individuals, who are authorized to issue notices of violation; andestablish, in respect of each violation, a short-form description to be used in notices of violation.ProceedingsIf a person who is designated under paragraph 36(a) believes on reasonable grounds that a person has committed a violation, the designated person may issue, and shall provide the person with, a notice of violation thatsets out the person’s name;identifies the alleged violation;sets out the penalty for the violation that the person is liable to pay; andsets out the particulars concerning the time and manner of payment.A notice of violation shall clearly summarize, in plain language, the named person’s rights and obligations under this section and sections 38 to 43.7, including the right to have the acts or omissions that constitute the alleged violation or the amount of the penalty reviewed and the procedure for requesting that review.PenaltiesIf the person named in the notice pays, in the prescribed time and manner, the amount of the penalty,they are deemed to have committed the violation in respect of which the amount is paid;the Minister shall accept that amount as complete satisfaction of the penalty; andthe proceedings commenced in respect of the violation under section 37 are ended.Instead of paying the penalty set out in a notice of violation, the person named in the notice may, in the prescribed time and manner,if the penalty is $5,000 or more, request to enter into a compliance agreement with the Minister that ensures the person’s compliance with the order or the provision to which the violation relates; orrequest a review by the Minister of the acts or omissions that constitute the alleged violation or the amount of the penalty.If the person named in the notice of violation does not pay the penalty in the prescribed time and manner and does not exercise any right referred to in subsection (2) in the prescribed time and manner, they are deemed to have committed the violation identified in the notice.Compliance AgreementsAfter considering a request under paragraph 38(2)(a), the Minister may enter into a compliance agreement, as described in that paragraph, with the person making the request on any terms and conditions that are satisfactory to the Minister. The terms and conditions mayinclude a provision for the giving of reasonable security, in a form and in an amount satisfactory to the Minister, as a guarantee that the person will comply with the compliance agreement; andprovide for the reduction, in whole or in part, of the penalty for the violation.A person who enters into a compliance agreement with the Minister is, on doing so, deemed to have committed the violation in respect of which the compliance agreement was entered into.If the Minister is satisfied that a person who has entered into a compliance agreement has complied with it, the Minister shall cause a notice to that effect to be provided to the person, at which timethe proceedings commenced in respect of the violation under section 37 are ended; andany security given by the person under the compliance agreement shall be returned to the person.If the Minister is of the opinion that a person who has entered into a compliance agreement has not complied with it, the Minister shall cause a notice of default to be provided to the person to the effect thatinstead of the penalty set out in the notice of violation in respect of which the compliance agreement was entered into, the person is liable to pay, in the prescribed time and manner, twice the amount of that penalty, and, for greater certainty, subsection 34(2) does not apply in respect of that amount; orthe security, if any, given by the person under the compliance agreement shall be forfeited to Her Majesty in right of Canada.Once provided with the notice of default, the person may not deduct from the amount set out in the notice any amount that they spent under the compliance agreement andthe person is liable to pay the amount set out in the notice; orif the notice provides for the forfeiture of the security given under the compliance agreement, that security is forfeited to Her Majesty in right of Canada and the proceedings commenced in respect of the violation under section 37 are ended.If a person pays the amount set out in the notice of default in the prescribed time and manner,the Minister shall accept the amount as complete satisfaction of the amount owing; andthe proceedings commenced in respect of the violation under section 37 are ended.If the Minister refuses to enter into a compliance agreement requested under paragraph 38(2)(a), the person who made the request is liable to pay the amount of the penalty in the prescribed time and manner.If a person pays the amount referred to in subsection (1),they are deemed to have committed the violation in respect of which the payment is made;the Minister shall accept the amount as complete satisfaction of the penalty; andthe proceedings commenced in respect of the violation under section 37 are ended.If a person does not pay the amount referred to in subsection (1) in the prescribed time and manner, they are deemed to have committed the violation identified in the notice of violation.Review by the MinisterOn completion of a review requested under paragraph 38(2)(b) with respect to the acts or omissions that constitute the alleged violation, the Minister shall determine whether the person who requested the review committed the violation. If the Minister determines that the person committed the violation but that the amount of the penalty was not established in accordance with the provisions of this Act and the regulations, the Minister shall correct the amount.If the Minister determines under subsection (1) that the person who requested the review did not commit the violation, the proceedings commenced in respect of it under section 37 are ended.On completion of a review requested under paragraph 38(2)(b) with respect to the amount of the penalty, the Minister shall determine whether the amount of the penalty was established in accordance with the provisions of this Act and the regulations and, if not, the Minister shall correct the amount.The Minister shall cause a notice of any decision made under subsection (1) or (3) to be provided to the person who requested the review.The person is liable to pay, in the prescribed time and manner, the amount of the penalty that is confirmed or corrected in the Minister’s decision made under subsection (1) or (3).If a person pays the amount referred to in subsection (5),the Minister shall accept the amount as complete satisfaction of the penalty; andthe proceedings commenced in respect of the violation under section 37 are ended.The Minister shall consider only written evidence and written submissions in determining whether a person committed a violation or whether the amount of a penalty was established in accordance with the provisions of this Act and the regulations.EnforcementThe following amounts constitute debts due to Her Majesty in right of Canada that may be recovered in the Federal Court :the amount of a penalty, from the time the notice of violation setting out the penalty is provided;every amount set out in a compliance agreement entered into with the Minister under subsection 39(1), from the time the compliance agreement is entered into;the amount set out in a notice of default referred to in subsection 39(4), from the time the notice is provided; andthe amount of a penalty as set out in a decision of the Minister made under subsection 41(1) or (3), from the time the notice of that decision is provided.No proceedings to recover a debt referred to in subsection (1) may be commenced later than five years after the debt became payable.A debt referred to in subsection (1) is final and not subject to review or to be restrained, prohibited, removed, set aside or otherwise dealt with except to the extent and in the manner provided by sections 38 to 41.Any debt referred to in subsection 42(1) in respect of which there is a default of payment, or the part of any such debt that has not been paid, may be certified by the Minister.On production to the Federal Court, the certificate shall be registered in that Court and, when registered, has the same force and effect, and all proceedings may be taken on the certificate, as if it were a judgment obtained in that Court for a debt of the amount specified in it and all reasonable costs and charges associated with the registration of the certificate.Rules About ViolationsA person named in a notice of violation does not have a defence by reason that the personexercised due diligence to prevent the violation; orreasonably and honestly believed in the existence of facts that, if true, would exonerate the person.Every rule and principle of the common law that renders any circumstance a justification or excuse in relation to a charge for an offence under this Act applies in respect of a violation to the extent that it is not inconsistent with this Act.In every case when the facts of a violation are reviewed by the Minister, he or she shall determine, on a balance of probabilities, whether the person named in the notice of violation committed the violation identified in the notice.If a person other than an individual commits a violation under this Act, any of the person’s directors, officers, agents or mandataries who directed, authorized, assented to, acquiesced in or participated in the commission of the violation is a party to and liable for the violation whether or not the person who actually committed the violation is proceeded against under this Act.A person is liable for a violation that is committed by any employee, agent or mandatary of the person acting in the course of the employee’s employment or the scope of the agent or mandatary’s authority, whether or not the employee, agent or mandatary who actually committed the violation is identified or proceeded against under this Act.A violation that is continued on more than one day constitutes a separate violation in respect of each day on which it is continued.Other ProvisionsIn any proceeding in respect of a violation or a prosecution for an offence, a notice of violation purporting to be issued under this Act is admissible in evidence without proof of the signature or official character of the person appearing to have signed the notice of violation.Proceedings in respect of a violation shall not be commenced later than six months after the Minister becomes aware of the acts or omissions that constitute the alleged violation.If an act or omission may be proceeded with either as a violation or as an offence, proceeding in one manner precludes proceeding in the other.A document appearing to have been issued by the Minister, certifying the day on which the acts or omissions that constitute the alleged violation became known to the Minister, is admissible in evidence without proof of the signature or official character of the person appearing to have signed the document and, in the absence of evidence to the contrary, is proof that the Minister became aware of the acts or omissions on that day.The Minister may, for the purpose of encouraging compliance with the provisions of this Act and the regulations, publish information about any violation after proceedings in respect of it are ended. — 2017, c. 7, s. 31The portion of section 45.1 of the Act before paragraph (a) is replaced by the following :The Minister may, by order, require a person who is authorized under this Act to conduct activities in relation to controlled substances or precursors, who imports designated devices or who conducts other activities referred to in section 46.4 to provide the Minister, in the time and manner that the Minister specifies, with any information respecting those activities that the Minister considers necessary — 2017, c. 7, s. 32Section 45.2 of the Act is replaced by the following :The Minister may, by order, require a person who is authorized under this Act to conduct activities in relation to controlled substances or precursors or who conducts activities referred to in section 46.4 in relation to designated devices, to take measures, in the time and manner that the Minister specifies, to prevent non-compliance with the provisions of this Act or the regulations or, if the Minister has reasonable grounds to believe that there is such non-compliance, to remedy it. — 2017, c. 7, s. 35Subsection 46.3(1) of the Act is replaced by the following :No person shall import into Canada a designated device unless they register the importation with the Minister and the person imports it in accordance with the regulations.Subsection 46.3(2) of the Act is amended by striking out “and” at the end of paragraph (e), by adding “and” at the end of paragraph (f) and by adding the following after paragraph (f):any other prescribed information. — 2017, c. 7, s. 36The Act is amended by adding the following before section 47:No person shall conduct a prescribed activity in relation to a designated device except in accordance with the regulations. — 2017, c. 7, ss. 40(12), (13)Subsection 55(1) of the Act is amended by striking out “and” at the end of paragraph (z.01) and by adding the following after that paragraph :governing, controlling, limiting, authorizing the importation into Canada, exportation from Canada, sale, provision, possession of or other dealing in any designated device or any class of designated devices;respecting the issuance, suspension, cancellation, duration and terms and conditions of any licence or class of licences or of any permit for the importation into Canada, exportation from Canada, sale, provision or possession of any designated device or class of designated devices; andSubsection 55(1) of the Act is amended by striking out “and” at the end of paragraph (z.03) and by adding the following after that paragraph :prescribing exportation from Canada, sale, provision, or possession of any designated device or any class of designated devices as activities for the purpose of section 46.4;respecting the circumstances in which, the conditions subject to which and the persons or classes of persons by whom any designated device or class of designated devices may be exported from Canada, sold, provided or possessed, as well as the means by which and the persons or classes of persons by whom such activities may be authorized;respecting the registration of activities in relation to any designated device or any class of designated devices for the purpose of section 46.4; and — 2018, c. 16, s. 199Subject to subsection (2), subsection 34(2) of the Act is replaced by the following:The maximum penalty for a violation is $1,000,000.Subsection (1) applies only if Bill C-37, introduced in the 1st session of the 42nd Parliament and entitled An Act to amend the Controlled Drugs and Substances Act and to make related amendments to other Acts receives royal assent. If that Act receives royal assent, then subsection (1) comes into force on the first day on which both section 28 of that Act and this subsection are in force. — 2024, c. 17, s. 413(4)Subsection 55(1.2) of the Act is repealed. — 2024, c. 17, s. 414Subsection 56(2) of the Act is repealed. — 2024, c. 17, s. 415Sections 56.1 and 56.2 of the Act are repealed.